CRBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Corbus Pharmaceuticals Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$4.46−0.06 (-1.33%)
Close on Oct 19, 2026
- Market cap
- $86.56M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$14.86 (−76.92%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $86.56M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.85
- Dividend yield
- –
- Free cash flow yield
- -74.51%
Fundamentals
- Net income
- -$101.90M
- EPS, diluted
- -$6.18
- Free cash flow
- -$64.50M
- Book value per share
- $5.27
- Diluted shares
- 19M
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$106.88M
Net income
-$101.90M
EPS, diluted
-$6.18
Free cash flow
–
Reported periodTrailing twelve months